202 related articles for article (PubMed ID: 4918921)
1. [Effect of a decarboxylase inhibitor (Ro 4-4602) in combination with L-dopa on inhibited depressions].
Matussek N; Benkert O; Schneider K; Otten H; Pohlmeier H
Arzneimittelforschung; 1970 Jul; 20(7):934-5. PubMed ID: 4918921
[No Abstract] [Full Text] [Related]
2. [Effect of a decarboxylase inhibitor (Ro 4-4602) and L-dopa on inhibited depressions. II. Experimental psychological studies].
Pohlmeier H; Schön I; Matussek N
Arzneimittelforschung; 1970 Jul; 20(7):932-3. PubMed ID: 4918920
[No Abstract] [Full Text] [Related]
3. [Therapy of Parkinsonism using L-dopa in combination with a decarboxylase inhibitor].
Stammler A; Vielhaber K
Fortschr Neurol Psychiatr Grenzgeb; 1972 Oct; 40(10):564-8. PubMed ID: 4565521
[No Abstract] [Full Text] [Related]
4. Levodopa combined with MK 486 (L-alpha methyldopahydrazine)--a peripheral decarboxylase inhibitor in Parkinson's disease.
Andrews CJ; Somerville B
Med J Aust; 1974 Mar; 1(12):429-32. PubMed ID: 4598384
[No Abstract] [Full Text] [Related]
5. [Advances in L-DOPA therapy for parkinsonism through combination with a decarboxylase inhibitor. Results of a long-term study].
Wälzholz U; Schönfelder H
Nervenarzt; 1972 Oct; 43(10):531-2. PubMed ID: 4628192
[No Abstract] [Full Text] [Related]
6. [Experiences in the treatment of Parkinson's disease with a combination drug: L-dopa plus decarboxylase inhibitor (Ro 8-0576)].
Steinhäusl H
Wien Med Wochenschr; 1973 Jun; 123(26):433-5. PubMed ID: 4578743
[No Abstract] [Full Text] [Related]
7. [Modifications of catecholamine metabolism under the effect of a decarboxylase inhibitor associated with L-dopa and desipramine in patients with depressive and parkinsonian syndromes].
Geissbuhler F; Bartholini G; Gaillard JM; Tissot R
Encephale; 1971; 60(3):189-209. PubMed ID: 5119348
[No Abstract] [Full Text] [Related]
8. L-dopa plus decarboxylase inhibitor in depression.
Matussek N; Benkert O; Schneider K; Otten H; Pohlmeier H
Lancet; 1970 Sep; 2(7674):660-1. PubMed ID: 4195791
[No Abstract] [Full Text] [Related]
9. [Quantitative rigor determination in Parkinson's disease. Myo-integration for therapy control of L-Dopa in combination with a decarboxylase inhibitor (Ro 8-0576)].
Gehlen W; Eisenlohr JJ
Nervenarzt; 1974 Jan; 45(2):22-9. PubMed ID: 4601993
[No Abstract] [Full Text] [Related]
10. [2-year experiences with a combination treatment of Parkinsonism with L-dopa and a decarboxylase inhibitor (Benserazid, Ro 4-4602)].
Birkmayer W; Linauer W; Mentasti M; Riederer P
Wien Med Wochenschr; 1974 Jun; 124(22):340-4. PubMed ID: 4275492
[No Abstract] [Full Text] [Related]
11. [Potentiation of the central effect of DOPA after selective inhibition of extracerebral decarboxylase].
Gaillard JM; Schaeppi R; Tissot R
Arch Int Pharmacodyn Ther; 1969 Aug; 180(2):423-37. PubMed ID: 5348411
[No Abstract] [Full Text] [Related]
12. [Treatment of Parkinson's syndrome with L-dopa and its methylated derivatives: 3-OMD and 4-OMD associated with a decarboxylase inhibitor. Clinical and biochemical study].
Tissot R; Bartholini G; Constantinidis J; Eisenring JJ; Geissbühler F; Yanniotis G; de Ajuriaguerra J
Schweiz Med Wochenschr; 1973 Oct; 103(42):1466-74. PubMed ID: 4750149
[No Abstract] [Full Text] [Related]
13. [Treatment of Parkinsonism with oral L-DOPA combined with a decarboxylase inhibitor (Ro IV 46.02)].
Tissot R; Gaillard JM; Guggisberg M; Gauthier G; de Ajuriaguerra J
Presse Med (1893); 1969 Apr; 77(17):619-22. PubMed ID: 5785081
[No Abstract] [Full Text] [Related]
14. [L-dopa therapy of Parkinson's syndrome. Comparison of pure L-dopa and the combination preparation L-dopa and decarboxylase inhibitor].
Görlich J; Markus E
Dtsch Med Wochenschr; 1972 Aug; 97(34):1246-8. PubMed ID: 5048316
[No Abstract] [Full Text] [Related]
15. Preliminary clinical experience with L-dopa in endogenous depressions.
Náhunek K; Svestka J; Kamenická V; Rodová A
Act Nerv Super (Praha); 1972; 14(2):101-2. PubMed ID: 4557141
[No Abstract] [Full Text] [Related]
16. [Parkinson's syndrome. 4 years of experience in treatment with L Dopa associated with a decarboxylase inhibitor. Clinical and biochemical study].
Tissot R; de Ajuriaguerra J
Nouv Presse Med; 1973 Feb; 2(5):315-6. PubMed ID: 4686226
[No Abstract] [Full Text] [Related]
17. [Therapy of Parkinson's syndrome with L-dopa and a decarboxylase inhibitor (Ro 4-4602). Course in 71 patients].
Ferel D
Schweiz Med Wochenschr; 1972 Jan; 102(3):88-94. PubMed ID: 4551909
[No Abstract] [Full Text] [Related]
18. [Clinical studies on the treatment of parkinsonism with the L-dopa and decarboxylase inhibitor Ro-4-4602 association].
Wajsbort J; Hemli JA; Alfandary I; Yahel M; Siegfried J
Wien Med Wochenschr; 1971 Oct; 121(42):741-5. PubMed ID: 5115985
[No Abstract] [Full Text] [Related]
19. [Potentiation of L-Dopa in parkinsonism by means of an inhibitor of peripheral decarboxylation].
Court J; Kase JC; Mena I; Palacios E
Rev Med Chil; 1973 Jun; 101(6):452-5. PubMed ID: 4764560
[No Abstract] [Full Text] [Related]
20. [Therapeutic association of L-dopa and an inhibitor of peripheral decarboxylase in Parkinsonism. Preliminary results].
De Divitiis E; Cerillo A; Tata MR; Decina A
Acta Neurol (Napoli); 1973; 28(2):208-12. PubMed ID: 4709076
[No Abstract] [Full Text] [Related]
[Next] [New Search]